ADVENTRX Pharmaceuticals to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
April 19 2004 - 11:00AM
PR Newswire (US)
ADVENTRX Pharmaceuticals to Present at the CIBC World Markets
Annual Biotechnology & Specialty Pharmaceuticals Conference SAN
DIEGO, April 19 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals
(BULLETIN BOARD: AVRX) announced today that the Company will
present at the CIBC World Markets Annual Biotechnology and
Specialty Pharmaceuticals Conference, to be held April 27-28 at New
York's Millennium Broadway Hotel. The presentation is scheduled for
Tuesday, April 27 at 9:00 am EDT. Nicholas Jon Virca, President and
CEO of ADVENTRX, will present the latest developments for the
Company's clinical programs, which include CoFactor(TM) for the
treatment of colorectal and pancreatic cancers, and
BlockAide/CR(TM), Thiovir(TM) and EradicAide(TM) for the treatment
of HIV/AIDS. In addition, Mr. Virca will provide an update on the
Company's recent financing and operational plans. About ADVENTRX
ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and
development company whose business strategy is to commercialize
leading edge medical research through licensing agreements with
prominent universities and research institutions. The Company
focuses on cancer and antiviral research to launch products that
either extend the usefulness of current therapies or replace
marginal therapies with new approaches to treatment. More
information on ADVENTRX can be found on the Company's website at
http://www.adventrx.com/. This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Such statements are made based on management's current expectations
and beliefs. Actual results may vary from those currently
anticipated based upon a number of factors, including uncertainties
inherent in the drug development process, the timing and success of
clinical trials, the validity of research results, and the receipt
of necessary approvals from the United States Food and Drug
Administration. The Company undertakes no obligation to release
publicly any revisions, which may be made to reflect events or
circumstances after the date hereof. Contacts: The Ruth Group
Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac,
Ph.D. 646-536-7028 DATASOURCE: ADVENTRX Pharmaceuticals CONTACT:
Investors: Stephanie Carrington, +1-646-536-7017, Media: Cynthia
Isaac, Ph.D., +1-646-536-7028, both of The Ruth Group, for ADVENTRX
Pharmaceuticals Web site: http://www.adventrx.com/
Copyright